Puma Biotechnology Inc (PBYI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has a cash flow conversion efficiency ratio of 0.111x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.42 Million) by net assets ($130.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PBYI net asset quality index to measure how much of total assets are equity-financed.
Puma Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PBYI cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Puma Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Puma Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIGLARI HLDGS CL. A
F:SQ7A
|
N/A |
|
Bumble Inc
NASDAQ:BMBL
|
0.105x |
|
Larvotto Resources Ltd
AU:LRV
|
-0.056x |
|
Patrimoine et Commerce SA
PA:PAT
|
0.027x |
|
Aurora Corp
TW:2373
|
-0.013x |
|
Jinlong Machinery Electronic
SHE:300032
|
0.078x |
|
Hunan Lead Power Dazhi Technology Inc Co
SHE:300530
|
-0.195x |
|
CellaVision AB
ST:CEVI
|
0.058x |
Annual Cash Flow Conversion Efficiency for Puma Biotechnology Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Puma Biotechnology Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see PBYI market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.34 Million | $41.80 Million | 0.321x | -24.08% |
| 2024-12-31 | $92.12 Million | $38.92 Million | 0.422x | -16.41% |
| 2023-12-31 | $53.44 Million | $27.01 Million | 0.505x | +169.00% |
| 2022-12-31 | $21.61 Million | $-15.83 Million | -0.732x | +91.32% |
| 2021-12-31 | $-2.45 Million | $20.65 Million | -8.442x | -6180.06% |
| 2020-12-31 | $-5.95 Million | $800.00K | -0.134x | -110.49% |
| 2019-12-31 | $17.46 Million | $22.38 Million | 1.281x | +282.40% |
| 2018-12-31 | $34.31 Million | $-24.10 Million | -0.703x | +78.29% |
| 2017-12-31 | $53.30 Million | $-172.50 Million | -3.236x | -379.22% |
| 2016-12-31 | $209.82 Million | $-141.70 Million | -0.675x | +9.95% |
| 2015-12-31 | $206.01 Million | $-154.50 Million | -0.750x | -13.71% |
| 2014-12-31 | $117.05 Million | $-77.20 Million | -0.660x | -0.63% |
| 2013-12-31 | $83.99 Million | $-55.05 Million | -0.655x | -92.03% |
| 2012-12-31 | $128.91 Million | $-44.00 Million | -0.341x | -916.91% |
| 2011-12-31 | $54.37 Million | $-1.83 Million | -0.034x | +99.97% |
| 2009-12-31 | $138.00 | $-16.82K | -121.848x | -2340.50% |
| 2008-12-31 | $-2.18K | $-11.83K | 5.438x | -- |
| 2007-12-31 | $0.00 | $-15.09 Million | x | -- |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more